Why Is ORIC PHARMACEUTICALS (ORIC) Stock Up Today?
By the Top Tier Newswire AI Desk · October 20, 2026 at 11:19 AM ET · reviewed against 3 wire stories
ORIC PHARMACEUTICALS (ORIC) is up +11.24% in the latest session. Our newswire has captured 3 stories on ORIC across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 55/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ORIC Pharmaceuticals shares rose 11.24% to $14.15 on Tuesday. The primary driver was the announcement of a conference call scheduled for October 23 to review Phase 1b data for enozertinib in non-small cell lung cancer patients. This event coincides with the ESMO Congress 2026 and features Dr. Joshua Sabari discussing the drug’s potential.
What Happened
ORIC Pharmaceuticals announced it will host a conference call and webcast on Friday, October 23, 2026, at 8:00 a.m. ET. The event will review Phase 1b enozertinib data in first-line NSCLC patients with EGFR atypical mutations. The company stated the presentation will occur in conjunction with the ESMO Congress 2026. Dr. Joshua Sabari is scheduled to discuss the clinical data and the therapeutic potential of enozertinib.
Recent analyst activity also contributed to the momentum. JP Morgan maintained an Overweight rating and raised its price target to $26. Leerink Partners initiated coverage with an Outperform rating and a $26 price target. BTIG also initiated coverage with a Buy rating and a $26 price target. Additionally, ORIC announced an agreement with Cancer Research UK to advance a potential CIP2A-targeted therapy into clinical development.
What The Data Shows
The stock opened at $12.65, a 0.6% gap down from the prior close of $12.72. The session low was $12.52 at 9:30 AM ET, while the session high reached $14.20 at 11:05 AM ET. Volume stood at 0.5 million shares, which is 0.3 times the three-month daily average. The company has a market capitalization of $1.3 billion and is unprofitable with a trailing twelve-month EPS of -1.35. The beta is 0.98. The 52-week range is $7.23 to $14.68. On October 20, 2026, the stock printed 29 fresh 52-week highs and one fresh 52-week low.
Recent insider activity shows five sells totaling $1.5 million over the last 90 days, with no buys. The most recent sale was by Director Richard A. Heyman on October 1, 2026. CFO Dominic Piscitelli sold shares on September 28 and September 24, 2026.
What To Watch
Investors will focus on the October 23, 2026 conference call at 8:00 a.m. ET. The event will provide detailed insights into the enozertinib clinical data being presented at ESMO Congress 2026.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ORIC · today's session (5-min) · +9.08% vs prior close · updated 2:53 PM ETAI sentiment, last 36h · averaged over 3 stories · 55/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
4h agoMarketChameleonBULLISH 58Product/PR
ORIC sets Oct. 23 call to spotlight enozertinib Phase 1b data for first-line NSCLC with EGFR atypical mutations
October 20, 2026
ORIC Pharmaceuticals announced an Oct. 23, 2026 conference call and webcast to review Phase 1b enozertinib data in first-line NSCLC patients with EGFR atypical mutations in conjunction with ESMO Congress 2026. The company also highlighted three ESMO poster presentations spanning enozertinib and rinzimetostat, with posters available for public viewing on Oct. 23.
1d agoGlobeNewswireNEUTRAL 53Product/PR
ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026
Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to treat...
1d agoBusiness InsiderNEUTRAL 53Product/PR
ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026
Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to treat...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →